

# Coking coal prices “going bonkers” as price increases rapidly

Coking coal prices are rising steeply, up around 73% since February this year so far, in part due to weather and other issues in Australia and China.

This is great news for our **Colonial Coal, {TSX.V: CAD}** who have over 400 million tons of coking coal at their Huegenot property in B.C. Canada.

This is hugely important news for the beleaguered coking coal sector after the years of decline, 10 straight quarters of declining prices.

**Colonial Coal {TSX.V: CAD}** looks cheaper than ever at these prices, and don't forget that the US\$ v the Canadian \$ is at 1:1.33, so US \$140 per ton of coal equates to \$180 in Canadian.

To read the full article please [CLICK HERE](#)

---

# POET Technologies Appoints Investor Relations Counsel

POET Technologies {TSX.V: PTK} have announced an investor relations deal at an average of \$9,000 over 16 months, plus a 60 day notice period.

## *Comment*

*This is the most generous IR agreement I have ever seen, effectively, with a 60 day notice period, they are paying an average of \$9,000 plus expenses for a MINIMUM of 18 months!*

*Normally IR agreements range from three to six months with a possibility of an extension, for a \$3,000 to \$5,000 per month retainer, but this is for three times that, guaranteed! This is way above the average at an "average of \$9,000 per month" for this type of deal..*

*This deal looks incredibly generous, let's hope they can deliver. I for one will be watching.....*

**POET Technologies Appoints Investor Relations Counsel**

01, 2016

OTC Disclosure & News Service

SAN JOSE, Calif., Sept. 01, 201- **POET Technologies {TSX.V: PTK}**, a developer of opto-electronics fabrication processes for the semiconductor industry, previously announced on August 30, 2016 that it appointed Shelton Group as the Company's Investor Relations counsel, effective immediately. In accordance with exchange requirements, the Company has filed an application for approval of the appointment with the TSX Venture Exchange.

Shelton Group is a strategic investor relations firm providing customized programs to public and private companies, with a specific focus on small and micro-cap technology companies. Through a dedication to value-added service and a national network of key strategic relationships, Shelton Group has built a trusted reputation with the financial community that produces results for emerging and established companies. The dedicated investor relations team has diverse experience across the capital markets and financial services industry as well as long-standing relationships with analysts and institutional investors. The firm represents clients based in the U.S. as well as international companies seeking increased exposure and visibility in the U.S. markets.

Shelton Group has been retained to create a proactive and strategic investor relations plan for POET that will strive to establish and support a best practices platform as it relates to the Company's communication with the Street and broader financial community. The goal of the program is to enhance the Company's messaging and positioning in order to diversify and expand the existing shareholder base, as well as increase the overall visibility and awareness of the Company with highly targeted groups of prospective investors, institutions,

analysts and the investment community as a whole.

The initial term of the agreement with Shelton Group will be 16 months, which will automatically renew unless cancelled by either party. **After the initial term, either party may terminate the agreement by providing a 60-day written notice to the other party.**

The agreement consists of a flat fee retainer of an average of approximately \$9,000 per month plus pre-approved expenses over the term of the engagement. Although activity will fluctuate during the course of the contract, the provisions of the agreement state that no overage charges will be assessed for additional hours spent on the Company's account.

Shelton Group has no interest, directly or indirectly, in the Company or its securities, and has no current right or intent to acquire such an interest during the initial term of the engagement. For more information about Shelton Group, please visit the company's website at [www.sheltongroup.com](http://www.sheltongroup.com). The appointment is subject to approval of the TSX Venture Exchange.

#### **About POET Technologies Inc.**

POET (Planar Opto-Electronic Technology) is a developer of opto-electronics and Photonic fabrication processes and products. Photonics integration is fundamental to increasing functional scaling and lowering the cost of current Photonic solutions. POET believes that its advanced opto-electronics process platform enables substantial improvements in energy efficiency, component cost and size in the production of smart

optical components, the engines driving applications ranging from data centers to consumer products to military applications. Silicon Valley-based POET's patented module-on-a-chip process, which integrates digital, high-speed analog and optical devices on the same chip, is designed to serve as an industry standard for smart optical components. More information may be obtained at [www.poet-technologies.com](http://www.poet-technologies.com).

ON BEHALF OF THE BOARD OF DIRECTORS

(signed) "John F. O'Donnell", Secretary

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" (within the meaning of applicable Canadian securities laws) and "forward-looking statements" (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as "anticipate", "believe", "expect", "plan", "intend", "potential", "estimate", "propose", "project", "outlook", "foresee" or similar words suggesting future outcomes or statements regarding an outlook. Such statements include the Company's expectations regarding the provision of the services of Shelton Group. They also include the Company's expectations with respect to the capability, functionality, performance and cost of the Company's technology.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things,

management's expectations regarding future growth, plans for and completion of projects by the Company's third party relationships, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, operational risks in the completion of the Company's anticipated projects, delays or changes in plans with respect to the development of the Company's anticipated projects by the Company's third party relationships, risks affecting the Company's ability to execute projects, the ability to attract key personnel, and the inability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company's securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward- looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

---

## **Cartier Resources issue new investor presentation**

**Cartier Resources {TSX.V: ECR}** have issued an updated investor presentation.

The share price has doubled during 2016 due to a rising gold price and a well managed prudent company.

**Cartier Resources {TSX.V: ECR}** are a well run company, very prudent in whatever they do, and have some excellent early stage projects in Quebec, where there are tax advantages to the company for spending money drilling.

To read the full article please [CLICK HERE](#)

---

## **Inovio to present at three prestigious American Biotech Conferences**

**Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** have announced that the Company will present a corporate overview at three prestigious American biotech conferences, details as follows;

### **Inovio Pharmaceuticals to Present at Upcoming Investment Conferences**

PLYMOUTH MEETING, PA – September 1, 2016 – **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** today announced that the Company will present a corporate overview at the following upcoming conferences:

Citi 11th Annual Biotech Conference

Mandarin Oriental, Boston, Thursday, September 8th, 1x1 meetings

23rd Annual Newsmakers in the Biotech Industry

Millennium Broadway Hotel, New York, Friday, September 9th, 11:00 am ET

Rodman & Renshaw 18th Annual Global Investment Conference

Lotte New York Palace Hotel, New York, Monday, September 12th, 2:35 pm ET

**A live and archived version of the Rodman & Renshaw presentation delivered by Inovio's CEO, Dr. J. Joseph Kim, will be available through the "Webcast" tab on Inovio's home page at [www.inovio.com](http://www.inovio.com) as well as at the following URL:**  
**<http://www.wsj.com/webcast/rrshq26/ino>**



---

# **Inovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic**

**Inovio Pharmaceuticals {NASDAQ: INO}** today announced it has initiated a clinical study of its preventive Zika vaccine (**GLS-5700**) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency.

## **Inovio Launches Zika Vaccine Trial in Midst of Puerto Rico Epidemic to Explore Early Signals of Vaccine Efficacy**

**Inovio's second human Zika vaccine study, a placebo-controlled 160-subject trial, will test for safety, immune responses and initial evidence of efficacy**

**PLYMOUTH MEETING, Pa. – August 29, 2016 – Inovio Pharmaceuticals {NASDAQ: INO}** today announced it has initiated a clinical study of its preventive Zika vaccine (**GLS-5700**) in 160 subjects in Puerto Rico, where the Zika virus outbreak has been declared a public health emergency.

The CDC estimates Zika will infect more than 25% of the Puerto Rican population by year end, providing the potential for this study's placebo control design to provide exploratory signals

of vaccine efficacy.

**Dr. J. Joseph Kim, Inovio's President & CEO**, said, *"The rapid progression of the Zika outbreak in Puerto Rico provides an immediate and unique opportunity to assess a preventive vaccine in a real world setting. Inovio and its collaborators are moving ahead with this second Zika vaccine clinical trial to evaluate safety, immune responses, and possible signals of vaccine efficacy. If the results are promising, we plan to meet with regulators in 2017 to map out the most efficient path forward to develop our Zika vaccine and help mitigate this widespread Zika outbreak that has expanded into the continental United States."*

Inovio is developing its Zika vaccine, GLS-5700, with **GeneOne Life Science, Inc. (KSE: 011000)** and academic collaborators from the US and Canada who are also working to advance Inovio's Ebola and MERS vaccines through clinical development.

In June, Inovio was the first to commence a human Zika trial, with sites in the U.S. and Canada. All 40 subjects for the first clinical study have been fully enrolled and dosed. Inovio expects to report results before the end of this year.

***There are no approved vaccines or therapies for Zika virus infection.*** While multiple companies and academic groups have announced development plans for Zika virus vaccines, only Inovio and a US government research center have started human clinical studies.

Inovio's second clinical study is a placebo-controlled, double-blind trial involving 160 healthy adult volunteers (80 subjects will receive vaccine and 80 subjects will receive placebo) to evaluate the safety, tolerability and immunogenicity of GLS-5700 administered with Inovio's CELLECTRA®-3P device.

This proprietary intradermal DNA vaccine delivery device has been shown to maximize antigen expression and immune responses in multiple human studies. Inovio will also assess differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. In pre-clinical testing, this synthetic vaccine induced robust antibody and T cell responses – the immune responses necessary to fight viral infections – in small and large animal models.

## **About the Zika Virus**

First identified in Uganda, Zika virus subsequently spread to equatorial Asia and over the past 10 years has rapidly spread through the South Pacific and into South America, Central America, and the Caribbean. Zika virus is a flavivirus, a family of viruses including yellow fever, dengue, and West Nile virus, which are introduced to people through mosquito bites. Because the Aedes species of mosquitoes that can potentially transmit Zika virus are found throughout the world there is concern that Zika will continue to spread to new countries and regions. As of August, 2016, 66 countries and territories reported evidence of mosquito-borne transmission of the Zika virus since 2015, compared to 33 countries stated by WHO in their first Zika situation report in February 2016. Zika can also be sexually transmitted.

The most common symptoms of Zika virus are fever, rash, joint pain, and conjunctivitis. Zika has been linked to a severe birth defect called microcephaly which arises in infants of women infected during pregnancy. Microcephaly is marked by an abnormally small head and incomplete brain development. Zika is also associated with Guillain-Barré syndrome, which causes muscle weakness of the limbs and in severe cases may cause almost total paralysis including the inability to breathe. Recent reports suggest Zika may also be linked to other neurological abnormalities and perhaps abnormalities in other body systems.

***No vaccine or therapy currently exists for the prevention or treatment of Zika virus infection.***

### **About GeneOne Life Science**

GeneOne Life Science, Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. VGXI manufactured the Zika vaccine and other emerging disease vaccines including Ebola and MERS.

### **About Inovio Pharmaceuticals, Inc.**

Inovio is taking immunotherapy to the next level in the fight

against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumblin Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit [www.inovio.com](http://www.inovio.com)

**CONTACT:**

Bernie Hertel

+1 858410 3101

[bhertel@inovio.com](mailto:bhertel@inovio.com)

---

**Barkerville      Gold      Mines  
reports    high    grade    drill**

# results at Cow Mountain

**Barkerville Gold Mines {TSX.V: BGM}** has reported Intersects of 10.02 g/t Au over 22.20 Metres Including 13.01 g/t Au over 11.50 Metres in Cow Mountain Phase I Drilling.

**Barkerville reports drill results from Cow Mountain.**

**Barkerville Gold Mines {TSX.V: BGM} Intersects 10.02 g/t (0.29 oz/t) Au over 22.20 Metres Including 13.01 g/t (0.38 oz/t) Au over 11.50 Metres in Cow Mountain Phase I Drilling**

VANCOUVER, BC- August 31, 2016 – **Barkerville Gold Mines Ltd. {TSX.V: BGM}** is pleased to announce results from the ongoing Phase I exploration and category conversion drilling program on Cow Mountain at the Company's flagship Cariboo Gold Project (CGP).

The results of these drillholes are presented in the full news release on the BARKerville website.

## **Drilling Highlights:**

BGM-16-419: 24.55 g/t (0.72 oz/t) Au over 3.30 metres including 47.00 g/t (1.37 oz/t) Au over 0.60 metres and 40.60 g/t (1.18 oz/t) Au over 1.30 metres

BGM-16-420: 32.62 g/t (0.95 oz/t) Au over 2.95 metres

including 61.20 g/t (1.79 oz/t) Au over 1.45 metres  
BGM-16-423: 12.30 g/t (0.36 oz/t) Au over 8.00 metres  
including 12.90 g/t (0.38 oz/t) Au over 1.50 metres and 69.90  
g/t (2.04 oz/t) Au over 0.50 metres and 31.00 g/t (0.90 oz/t)  
Au over 0.90 metres

BGM-16-446: 12.80 g/t (0.37 oz/t) Au over 2.50 metres  
including 16.50 g/t (0.48 oz/t) Au over 0.50 metres and 41.30  
g/t (1.20 oz/t) Au over 0.50 metres

BGM-16-447: 16.43 g/t (0.48 oz/t) Au over 2.40 metres  
including 23.00 g/t (0.67 oz/t) Au over 1.25 metres and 9.28  
g/t (0.27 oz/t) Au over 1.15 metres

BGM-16-451: 51.00 g/t (1.49 oz/t) Au over 1.75 metres  
including 172.50 g/t (5.03 oz/t) Au over 0.50 metres

BGM-16-451: 10.02 g/t (0.29 oz/t) Au over 22.20 metres  
including 13.01 g/t (0.38 oz/t) Au over 11.50 metres including  
27.60 g/t (0.81 oz/t) Au over 1.50 metres and 43.90 g/t (1.28  
oz/t) Au over 1.00 metres

BGM-16-456: 32.62 g/t (0.95 oz/t) Au over 4.50 metres  
including 46.04 g/t (1.34 oz/t) Au over 3.10 metres

BGM-16-457: 14.77 g/t (0.43 oz/t) Au over 5.75 metres  
including 18.98 g/t (0.55 oz/t) Au over 2.00 metres including  
19.00 g/t (0.55 oz/t) Au over 1.00 metres and 24.50 g/t (0.71  
oz/t) Au over 1.75 metres

BGM-16-458: 15.96 g/t (0.47 oz/t) Au over 3.00 metres  
including 27.20 g/t (0.79 oz/t) Au over 1.00 metres and 14.45  
g/t (0.42 oz/t) Au over 1.00 metres

BGM-16-459: 39.93 g/t (1.16 oz/t) Au over 3.50 metres  
including 10.05 g/t (0.29 oz/t) Au over 0.70 metres and 78.20  
g/t (2.28 oz/t) Au over 1.30 metres and 20.70 g/t (0.60 oz/t)  
Au over 1.50 metres

BGM-16-461: 52.59 g/t (1.53 oz/t) Au over 5.20 metres  
including 27.20 g/t (0.79 oz/t) Au over 0.80 metres and 232.00  
g/t (6.77 oz/t) Au over 0.50 metres and 108.50 g/t (3.16 oz/t)  
Au over 0.90 metres

**\*Note: Reported core lengths represent 50-75% true widths.**

## **Cow Mountain Phase I Drilling**

As per the Company's directive to optimise a new, geologically constrained gold resource at Cow Mountain potentially amenable to either open pit and or underground mining methods, 242 drill holes totaling 32,290 metres have now been completed in the 2016 Phase I drilling program.

Assay results for the final 40 drill holes are pending and will be made public once available. The purpose of the Cow Mountain 2016 campaign was to confirm and upgrade auriferous drill intersections by previous operators from 1938-1981 that were classified as inferred mineralisation because of lessened data confidence and not simply a function of wider drill hole spacing. The 2016 Phase I program was explicitly targeting these areas by replacing the historical gold intersections with modern drilling that conforms to CIM best practices and QAQC procedures. Based upon the 2016 drilling results to date, there has been excellent correlation between the historic mineralized intervals and the new 2016 drilling.

## **Island Mountain Exploration Update**

With the Cow Mountain drilling now completed, three drill rigs have been mobilized to Island Mountain and are currently performing a first pass, 20,000 metre Phase I drilling program. The vein style of gold mineralisation that dominates on Cow Mountain also occurs on Island Mountain but was never the primary focus of exploration or past development because of the incidence of higher grade massive sulphide replacement style mineralised bodies. As such, the 2016 Phase I program is designed to determine the extents of these vein systems, as well as test the down plunge extensions of the replacement bodies in areas that have never been drilled.



## **Qualified Persons**

Exploration activities at the Cariboo Gold Project are jointly administered on site by the Company's Project Managers, Maggie Layman, P.Geo. and Wanda Carter, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

## **Quality Assurance – Quality Control**

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company's secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to ALS Geochemistry's analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies

with established data acceptance criteria. The entire sample is crushed and 250 grams is pulverised. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 5ppb and upper limit of 10,000ppb. Samples with gold assays greater than 10,000ppb are re-analyzed using 50g fire assay with gravimetric finish, as well as 1,000g screen metallic fire assay. Samples are also analysed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

**For further information on Barkerville Gold Mines Ltd. please contact:**

Chris Lodder  
President & Chief Executive Officer  
Suite 400-365 Bay Street  
Toronto, Ontario, Canada  
[clodder@barkervillegold.com](mailto:clodder@barkervillegold.com)

### **About Barkerville Gold Mines Ltd.**

The Company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. Barkerville's mineral tenures cover 1,164 square kilometres along a strike length of 60 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by Barkerville in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of ore milled producing 25,464 ounces of

gold. The Company has completed a number of drilling and exploration programs over the past 20 years and is currently compiling this data with all historical information in order to develop geologic models which will assist new management and provide the framework to continue to explore the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

---

## **Avalon      issue      Separation Rapids    update**

**Avalon Advanced Materials {TSX: AVL}** reported that further to the Company's news release dated July 25, 2016, the Preliminary Economic Assessment ("PEA") on the Separation Rapids Lithium Project is now targeted for completion by mid-September, 2016.

### **Avalon update on their Separation Rapids PEA**

Toronto, ON – **Avalon Advanced Materials Inc. {TSX: AVL}** reports that further to the Company's news release dated July 25, 2016, the Preliminary Economic Assessment ("PEA") on the Separation Rapids Lithium Project is now targeted for completion by mid-September, 2016.

Work continues towards finalizing the hydrometallurgical process plant cost estimates, the mine plan and the economic model. Some delays were experienced in receiving final analytical results from the laboratory which has delayed completion of the PEA. Most of the other components of the PEA, including the updated resource estimate and environmental studies, have now been completed.

The technical information included in this news release has been reviewed and approved by the Company's Senior Vice President, Metallurgy and Technology Development, Mr. David Marsh, FAusIMM (CP), and Donald S. Bubar, P.Geo., both Qualified Persons under NI 43-101.

#### **About Avalon Advanced Materials Inc.**

Avalon Advanced Materials Inc. (formerly Avalon Rare Metals Inc.) is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology. The Company has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.

For questions and feedback, please e-mail the Company at [ir@AvalonAM.com](mailto:ir@AvalonAM.com)

or

Don Bubar, President & CEO at +1 416 364 4938

---

# New criticism of Nymox after latest news releases from the company

Nymox Pharma {NASDAQ: NYMX} is the the subject of new criticism following the recent article attacking the company.

Bizarrely the share price has doubled since the last revelation, although it has fallen back after the second critical article.

Nymox Pharma very volatile after criticism and recent news releases.

The share price of Nymox Pharma {NASDAQ: NYMX} halved after a recent article was published criticising the company and making allegation of impropriety.

The company has failed to respond tot he criticism, but instead ignored it and simply issued new releases claiming success for their recent trials.

Now another critical article has appeared, and once again the share price fell dramatically, but once again the company has issued a positive nes release and the share price is once

again climbing.

To read the full article please [CLICK HERE](#)

To read the full news release on PDF please [click HERE](#)

---

# **Bolivian Deputy Interior Minister beaten to death by striking miners**

A Bolivian government minister has been beaten to death by striking mineworkers after being kidnapped, the government has reported.

Rodolf Illanes, deputy interior minister, had gone to talk to protesting workers on Thursday in Panduro, around 100 miles from the de facto capital, La Paz, but was intercepted and kidnapped.

[\*Comment\*](#)

*[Sadly this comes as a result of lower metal prices leading to poor worker wages in Bolivia.](#)*

*It's incredibly sad that a man that went to try and resolve the situation has been killed like this, and goes to highlight the dangers of mining in the more risky jurisdictions.*

To read the full article please [CLICK HERE](#)

---

## Scorpio Gold announce Q2 2016 results

**Scorpio Gold {TSX.V: SGN}** have announced their Q2 2016 results and Management discussion.

10,089 ounces of gold were produced at the Mineral Ridge mine, compared to 8,738 ounces produced during Q2 of 2015.

Scorpio Gold Q2 2016 results highlights.

- 10,015 ounces of gold sold, compared to 10,217 ounces sold during Q2 of 2015.
- Revenue of \$12.4 million, compared to \$12.1 million during Q2 of 2015.
- Total cash cost per ounce of gold sold of \$879, compared to \$800 during Q2 2015.
- Mine operating earnings of \$3.1 million, compared to \$2.4 million during Q2 2015.
- Net earnings of \$1.2 million compared to \$1.7 million during

Q2 2015.

□ Adjusted net earnings (1) of \$2.2 million, compared to \$1.8 million during Q2 2015.

□ Adjusted EBITDA (1) of \$2.8 million, compared to \$2.9 million during Q2 of 2015.

□ Cash flow from operating activities of \$4.9 million, compared to \$4.6 million during Q2 of 2015.

□ *On August 3, 2016, the Second Judicial District Court of Washoe County, Nevada issued an oral ruling for summary judgment awarding a drilling company, National EWP, Inc. ("National"), US\$2.3 million in its lawsuit against the Company's 70% indirectly owned subsidiary Mineral Ridge Gold, LLC ("MRG"), the operator of the Mineral Ridge gold operation. The Company and its legal advisors strongly disagree with both the Court's legal conclusions and its factual findings, and it is currently evaluating its options to contest the ruling and stay execution of the judgement, once entered. (See Contingencies).*

---

## **Numis Securities increase Condor Gold target price**

**Condor Gold {AIM: CNR}** has had a "buy" rating and an increased target price of 130p given by London broker Numis Securities.

Their previous target was 115p.



**Numis Securities** are one of only two brokers currently covering Condor Gold.

The other one, **Beaufort**, has a “speculative buy” rating, and no target price.

The share price of Condor Gold has risen 150% so far in 2016.

---

## Storedot wins court case

StoreDot, Israel based nanotechnology materials pioneer known for its super-fast battery charging technology, announced that the Tel Aviv District Court has decided in favor of StoerDot, and to dismiss the lawsuit filed by Ramot, with prejudice.

HERZLIYA, Israel, August 24, 2016

**StoreDot**, Israel based nanotechnology materials pioneer known for its super-fast battery charging technology, is announcing today that the Tel Aviv District Court has decided in favor of StoerDot, and to to dismiss the lawsuit filed by Ramot with prejudice.

In its suit, Ramot claimed that StoreDot had breached its License Agreement with Ramot and that StoreDot's innovative technology stems from research done at Tel Aviv University. Ramot also claimed that StoreDot's groundbreaking Intellectual Property (IP) is related to Service Inventions created by TAU researchers.

Tel Aviv District Court has appointed two experts, respected professors in their fields, in order to evaluate Ramot's claims and StoreDot's technology. The experts had unambiguously reached the conclusion that Ramot had presented baseless claims.

In light of the expert's opinion, Ramot retracted from its claim against StoreDot following the court's recommendation to do so. Therefore, the court overruled the suit with prejudice.

*"We are very pleased with court's ruling, but we're not surprised," said Dr. Doron Myersdorf, CEO and Co-Founder at StoreDot. "I'm sure that Ramot, like other shareholders in the company, will continue to benefit from being StoreDot's pioneering partners, and from our patented technological breakthroughs such as the FlashBattery™ designed for both smartphone and electric vehicles."*

## **About StoreDot:**

StoreDot Ltd. is an innovation leader in materials and device applications, developing ground-breaking technologies based on a unique methodology for the design, synthesis, and

manufacturing of organic compounds.

Designed to replace known technologies by means of enhanced chemical, electrical, and optical properties, StoreDot's proprietary technology, inspired by nature, can be optimized for multiple industries including fast-charging batteries in mobile devices, electric vehicles and for next generation LCD displays.

Alona Stein | PR Supervisor | +972-507782344

**SOURCE:** StoreDot.

---

## Will Strongbow Exploration's plans be ruined by a falling tin price?

**Strongbow Exploration {TSX.V: SBW}** are planning to reopen the South Crofty former producing tin mine in Cornwall, UK.

South Crofty was closed due to low tin prices, but looks sustainable at the current price of tin, but how long will it stay this high as a new, unexpected source of tin emerges, Myanmar?

[Comment](#)

*One of the huge problems of investing in the mining sector is the slow pace of progress, from original project conception through to eventual production.*

*Along the way there are multiple financings, various EIA's, feasibility studies, placings, production decisions, capex to be raised etc.etc. The time lag from start to finish, often ten years or more, can result in world events taking over, and a project that looked profitable and attractive in the early stages, becoming unsustainable as metal prices crash as the bull cycle ends.*

*It was refreshing to see **Strongbow Exploration** propose to reopen the South Crofty tin mine in Cornwall, as it was only closed 20 years or so ago, it is much closer to potentially producing than an early stage project up in the Yukon, for example.*

*With the world price of tin looking good, at around \$18,000 per ton, the project looks attractive, and credible. But just as often happens, something occurs that may knock the best laid plans off track. In this case it is the fact that the country of Myanmar has begun exporting tin to China, and as a result, may cause a glut, and a reduction in price.*

*The full details can be read in the Daily Mail article below, but I for one hope that tin process remain high and South Crofty once again mines tin and adds to the reviving British mining scene.*

To read the full article please [CLICK HERE](#)

---

# **Inovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumblin Life Sciences**

**Inovio Pharmaceuticals {NASDAQ: INO}** announced it has licensed a veterinary vaccine for foot and mouth disease to **Plumblin Life Sciences {KONEX: 222670}**, an animal health company listed and headquartered in South Korea.

**Inovio Licenses Veterinary Foot and Mouth Disease Vaccine to Plumblin Life Sciences**

2016-08-16 08:00 ET – News Release

PLYMOUTH MEETING, Pa., Aug. 16, 2016- **Inovio Pharmaceuticals {NASDAQ: INO}** today announced it has licensed a veterinary vaccine for foot and mouth disease (FMD) to **Plumblin Life Sciences {KONEX: 222670}**, an animal health company headquartered in South Korea.

Plumblin will fund all development activities for this FMD vaccine. Inovio will receive milestone payments as well as royalties on product sales from Plumblin for commercial rights to this FMD synthetic vaccine in Asia, excluding Japan. In 2014, Inovio sold other animal health assets to Plumblin for cash and a significant equity position in the company.

Inovio's FMD DNA vaccine administered to sheep and pigs in previous studies showed strong protective neutralizing antibodies, demonstrating its potential to prevent the virus from infecting livestock animals.

The FMD virus is one of the most infectious diseases affecting farm animals including cattle, swine, sheep and goats, and is a serious threat to global food safety. Once an area is exposed to FMD, livestock & dairy exports are ceased and herds are culled. For example, in a major FMD outbreak in the U.K. in 2001 more than four million animals were slaughtered, resulting in more than \$10 billion (USD) in economic losses. In a 2011 FMD epidemic in South Korea, more than 3.3 million animals, mostly swine, were culled in an attempt to keep the disease from spreading.

Because FMD can spread rapidly and beyond regional boundaries there is a need to develop vaccines that can simultaneously target different regional serotypes of FMD in a single vaccine. Inovio's SynCon® technology enables rapid development of vaccines that can cover multiple serotypes simultaneously with a single formulation. Inovio has generated and tested DNA vaccine constructs targeting all seven main FMD virus serotypes.

**Dr. J. Joseph Kim** said, *"With Inovio's focus on human immunotherapies to fight cancers and infectious diseases, we want to monetise non-core assets. This is our second license agreement with Plumblin to enable the development of animal health products and market opportunities. FMD pandemics are a worldwide threat to food supply and society for which Inovio's FMD vaccine could provide a global solution."*

### **About Plumblin Life Sciences, Inc.**

Plumblin Life Sciences, Inc., an animal biopharmaceutical company, focuses on companion animals. It develops deoxyribonucleic acid (DNA)-based vaccines and therapies for animals using plasmid-based DNA delivery and expression technology by electroporation to optimize an animal's natural biological and immunological potential.

The company's solutions include growth hormone releasing hormone (GHRH), a naturally occurring molecule; and an electroporation technology for delivering plasmids into skeletal muscle cells and skin. It offers products for dog cancer/anemia, equine laminitis, cat renal failure/anemia, dog renal failure/anemia, and swine GHRH. Plumblin Life Sciences, Inc. is based in Seoul, South Korea.

### **About Inovio Pharmaceuticals, Inc.**

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile.

With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumblin Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, [www.inovio.com](http://www.inovio.com)

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective



than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended June 30, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

**CONTACT:**

Bernie Hertel

+1 858-410-3101

[bhertel@inovio.com](mailto:bhertel@inovio.com)

---

# Jim Grant Wall St. Expert predicts a “bad ending”, and bets on Gold

**James Grant**, Wall Street expert and editor of the investment newsletter **Grant's Interest Rate Observer**, warns of a crash in sovereign debt, and bets on gold.

His prediction is this will end in tears.

To read the full article please [CLICK HERE](#)

---

## Zenyatta strengthens their Corporate Communications and IR team

**Zenyatta Ventures {TSX.V: ZEN}** announced the appointment of Ms. Mara Strazdins as VP Corporate Communications and Investor Relations.

Ms Strazdins is an industry veteran of some 30 years standing, and will become the focal point of the Zenyatta IR team.

**Zenyatta Hires VP Corporate Communications & Investor Relations to Further Strengthen the Team for a Strategic and Active Marketing Program**

THUNDER BAY, ON- August 18, 2016) – **Zenyatta Ventures {TSX.V: ZEN}** is pleased to announce the appointment of Ms. Mara Strazdins as VP Corporate Communications and Investor Relations.

The appointment of Ms. Strazdins is a key component in Zenyatta's strategy to raise their profile with current and potential investors as the Company moves forward with the development of the Albany Graphite Project.

**Aubrey Eveleigh, President and CEO**, stated, *"We are delighted to attract a professional of Mara's caliber to our existing Zenyatta team. Ms. Strazdins is an individual with a strong technical and investor relations background. She will play a very important role during the awareness and development of Zenyatta's unique hydrothermal graphite deposit. We are looking forward to getting this story out to a wider audience and working closely with Ms. Strazdins to achieve this goal."*

Ms. Strazdins has a HB.Sc. (Geology) from University of Toronto and Public Relations from Ryerson University, Toronto, Ontario with over 30 years of experience in the mining/investor relations sector. Prior to joining Zenyatta, Mara worked as VP Investor Relations and Corporate Communications for Duluth Metals Limited, Wallbridge Mining Limited and CHF Investor Relations. Prior to that she worked

as a geologist with Placer Dome for 18 years and obtained a varied range of experience within their North American corporate structure. With a diversified background in geology, exploration and public relations, Ms. Strazdins will be focusing on raising the Company's visibility within the investment community.

### **About Zenyatta Ventures Ltd.**

Zenyatta continues to develop its rare volcanic-hosted Albany graphite deposit in Ontario, Canada. The Company's highly crystalline graphite deposit is fluid derived rather than the typical and abundant sedimentary (flake) style of graphite deposits. Albany is the only and largest graphite deposit of its kind under development in the world. It is situated 30 km north of the Trans-Canada Highway, power line and natural gas pipeline near the communities of Constance Lake First Nation and Hearst. A rail line is located 70 km away with an all-weather road approximately 10 km from the graphite deposit. The world trend is to develop products for technological applications that need extraordinary performance using high-purity graphite powder at an affordable cost. Albany graphite can be upgraded with very good crystallinity without the use of aggressive acids (hydrofluoric) or high temperature thermal treatment therefore having an environmental advantage over other types of upgraded high-purity graphite material.

The outlook for the global graphite market is very promising with demand growing rapidly from new applications. It is now considered one of the more strategic elements by many leading industrial nations, particularly for its growing importance in high technology manufacturing and in the emerging "green" industries such as electric vehicle components. The application for graphitic material is constantly evolving due

to its unique chemical, electrical and thermal properties. It maintains its stability and strength under temperatures in excess of 3,000°C and is very resistant to chemical corrosion. It is also one of the lightest of all reinforcing elements and has high natural lubricating abilities. Some of these key physical and chemical properties make it critical to modern industry.

Mr. Aubrey Eveleigh, P.Geo., Zenyatta's President and CEO, is the "Qualified Person" for the purposes of National Instrument 43-101 and has reviewed, prepared and supervised the preparation of the technical information contained in this news release.

CAUTIONARY STATEMENT: This analysis does not represent a statistically large sample size. Furthermore, these positive results do not mean that Zenyatta can extract and process Albany graphite for graphite applications on an economic basis. Without a formal independent feasibility study, there is no assurance that the operation will be economic. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward looking information and Zenyatta cautions readers that forward looking information is based on certain assumptions and risk factors that could cause actual results to differ materially from the expectations of Zenyatta included in this news release. This news release includes certain "forward-looking statements", which often, but not always, can be identified by the use of words such as "believes", "anticipates", "expects", "estimates", "may", "could", "would", "will", or "plan". These statements are based on information currently available to Zenyatta and Zenyatta provides no assurance that actual

results will meet management's expectations. Forward-looking statements include estimates and statements with respect to Zenyatta's future plans, objectives or goals, to the effect that Zenyatta or management expects a stated condition or result to occur, including the expected timing for release of a pre-feasibility study, the expected uses for graphite in the future, and the future uses of the graphite from Zenyatta's Albany deposit. Since forward-looking statements are based on assumptions and address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results relating to, among other things, results of metallurgical processing, ongoing exploration, project development, reclamation and capital costs of Zenyatta's mineral properties, and Zenyatta's financial condition and prospects, could differ materially from those currently anticipated in such statements for many reasons such as, but are not limited to: failure to convert estimated mineral resources to reserves; the preliminary nature of metallurgical test results; the inability to identify target markets and satisfy the product criteria for such markets; the inability to complete a prefeasibility study; the inability to enter into offtake agreements with qualified purchasers; delays in obtaining or failures to obtain required governmental, environmental or other project approvals; political risks; uncertainties relating to the availability and costs of financing needed in the future; changes in equity markets, inflation, changes in exchange rates; fluctuations in commodity prices; delays in the development of projects; capital and operating costs varying significantly from estimates and the other risks involved in the mineral exploration and development industry; and those risks set out in Zenyatta's public documents filed on SEDAR. This list is not exhaustive of the factors that may affect any of Zenyatta's forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on Zenyatta's forward-looking statements. Although Zenyatta believes that the assumptions and factors

used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zenyatta disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

For Further Information: [www.zenyatta.ca](http://www.zenyatta.ca)

or contact:

Mara Strazdins, HB.Sc.

VP Corporate Communications and Investor Relations

---

## **Cartier closes \$150,000 placing**

**Cartier Resources {TSX.V: ECR}** have announced the closing of a placing for \$150,000, non flow through.

**Cartier Resources {TSX.V: ECR}** have demonstrated that things are still tough for the junior explorers by announcing such a small raising.

Two thirds of the money has been pledged by directors of an IR firm just engaged by Cartier!

---

## Neometals partner looks for around \$700 million for their Mt. Marion stake

Neometals {ASX: NMT} partner in their MT.Marion lithium project, Mineral Resources {ASX: MIN} is looking to divest their stake in the project.

The Australian newspaper reports they are looking for a price of around \$700 million.

[To read the full article please CLICK HERE](#)

***N.B. to read this article ad blockers have to be turned off for the site.***

---



# **Strongbow Exploration featured in an FT article**

**Strongbow Exploration {TSX.V: SBW}** is looking to be part of a small revival in metal mining in the UK. aiming to reopen the South Crofty former producing tin mine, in Cornwall.

Strongbow has been featured on an article in the Financial Times after their recent press day.

To read the full article please [CLICK HERE](#)

---

## **Barkerville Gold Completes Acquisition of Williams Creek Gold**

**Barkerville Gold Mines {TSX.V: BGM}** and **Williams Creek Gold Ltd. {TSX.V: WCX}** are pleased to announce that Barkerville has acquired all of the issued and outstanding common shares of Williams Creek by way of plan of arrangement under the Business Corporations Act of B.C., Canada.

### **Barkerville Gold Completes Acquisition of Williams Creek Gold**

August 16, 2016 – Vancouver, B.C. – **Barkerville Gold Mines {TSX.V: BGM}** and **Williams Creek Gold Ltd. {TSX.V: WCX}** are pleased to announce that Barkerville has acquired all of the

issued and outstanding common shares of Williams Creek by way of plan of arrangement under the Business Corporations Act (British Columbia) (the “Arrangement”).

The Arrangement was approved by shareholders of Williams Creek at a special meeting of shareholders held on August 8, 2016 and approved by the Supreme Court of British Columbia on August 11, 2016.

Pursuant to the terms of the Arrangement, Williams Creek shareholders are now entitled to receive 0.062352572 of a common share of Barkerville (each whole common share, a “Barkerville Share”) for each one common share of Williams Creek (a “Williams Creek Share”) held by such Williams Creek shareholders. In total, Barkerville has issued 6,799,989 Barkerville Shares in exchange for all of the issued and outstanding Williams Creek Shares held by Williams Creek shareholders.

Effective today, Williams Creek has become a wholly owned subsidiary of Barkerville and, collectively, former shareholders of Williams Creek will hold approximately 2.25% of the issued and outstanding Barkerville Shares, and the Williams Creek Shares will be delisted from the TSX Venture Exchange.

In order to receive their Barkerville Shares, Williams Creek shareholders are required to surrender their Williams Creek Share certificates to the depositary, Computershare Investor Services Inc., together with a properly completed letter of transmittal. A copy of the letter of transmittal was mailed to

the registered shareholders of Williams Creek and is also available for viewing on SEDAR under the Williams Creek profile at [www.sedar.com](http://www.sedar.com)

### **About Barkerville Gold:**

Barkerville is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia.

Barkerville's mineral tenures cover 1,164 square kilometres along a strike length of 60 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by Barkerville in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of ore milled producing 25,464 ounces of gold. Barkerville has completed a number of drilling and exploration programs over the past 20 years and is currently compiling this data with all historical information in order to develop geologic models which will assist new management and provide the framework to continue to explore the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

**For further information please contact:**

Chris Lodder

President & Chief Executive Officer

